Table 4.
Odds for worsening of clinical and radiographic outcomes (RCAL, ABH and ABD) over two years, in groups with circulating levels of MMP-2 in the second and third tertiles, compared to odds of worsening in group with circulating MMP-2 levels in lowest (first) tertile.
| Odds ratios (OR) and 95% CI (in parentheses) for worsening of clinical and radiographic outcomes over 24 months since baseline | ||||||||
|---|---|---|---|---|---|---|---|---|
| Comparison | RCAL | ABH | ABD | |||||
| Placebo * (n=62) | SDD * (n=51) | Smokers** (n=23) | Non-Smokers** (n=90) | |||||
| Concurrent Levels of MMP-2 |
2nd tertile vs 1st | OR=1.19 (0.62, 2.30) p=0.61 |
OR=0.73 (0.39, 1.37) p=0.32 |
OR=1.83 (0.83,4.04) p=0.13 |
OR=2.99 (1.43, 6.23) p=0.0035 |
OR=0.76 (0.42, 1.37) p=0.35 |
||
| 3rd tertile vs 1st | OR=2.07 ( 1.14, 3.76) p=0.017 |
OR=1.77 ( 1.05, 2.99) p=0.032 |
OR=1.52 (0.72, 3.18) p=0.27 |
OR=2.62 (1.02, 6.73) p=0.046 |
OR=1.24 (0.73, 2.11) p=0.42 |
|||
| Baseline levels of MMP-2 | ||||||||
|
Within five years
of menopause*** (n=42) |
More than five years post-menopause*** (n=71) |
|||||||
| 2nd tertile vs 1st | OR=0.75 (0.37, 1.54) p=0.43 |
OR=0.90 (0.55, 1.48) p=0.67 |
OR=2.44 (1.04, 5.76) p=0.041 |
OR=0.94 (0.52, 1.71) p=0.85 |
||||
| 3rd tertile vs 1st | OR=1.48 (0.90, 2.42) p=0.12 |
OR=0.99 (0.64, 1.54) p=0.98 |
OR=4.54 (2.04, 10.10) p=0.0002 |
OR=0.78 (0.42, 1.44) p=0.42 |
||||
Significant associations (p<0.01) between measures of disease progression (RCAL, ABH and ABD) and serum levels of MMP-2 are noted in italics. All associations were examined for effect modification by treatment group, time since menopause, and smoking status. Because adjustment for these covariates did not affect model estimates, unadjusted odds ratios are presented.
Multivariable models of alveolar bone height (ABH) detected effect modification between treatment status and concurrent measures of MMP-2 (p=0.0782). Therefore, analyses that relate ABH to concurrent measures of MMP-2 are stratified by treatment status.
Multivariable models of alveolar bone density (ABD) detected effect modification between smoking status and concurrent measures of MMP-2 (p=0.0886). Therefore, analyses that relate ABD to concurrent measures of MMP-2 are stratified by smoking status.
Multivariable models of alveolar bone density (ABD) detected effect modification between post-menopausal status and baseline measures of MMP-2 (p=0.0097). Therefore, analyses that relate ABD to baseline measures of MMP-2 are stratified by post-menopausal status.